Novartis AG Eyes Israeli Companies

Novartis AG (NYSE: NVS), the world's biggest pharmaceutical company, recently increased its interest in Israel. For a long time, the company was active in marketing and clinical trials in Israel, and now it is involved in investment as well.

Over the past year, Novartis has invested $35 million in Israel’s Gamida Cell, with an option to acquire it in the future for $165 million, plus royalties, by mid-2016. Novartis also signed a deal with BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX), under which BioLineRx will seek and develop Israeli technologies for Novartis.

Help employers find you! Check out all the jobs and post your resume.

Back to news